JP2009504622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504622A5 JP2009504622A5 JP2008525620A JP2008525620A JP2009504622A5 JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5 JP 2008525620 A JP2008525620 A JP 2008525620A JP 2008525620 A JP2008525620 A JP 2008525620A JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- psychosis
- dihydrotetrabenazine
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000028017 Psychotic disease Diseases 0.000 claims 14
- 201000000980 schizophrenia Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 5
- 206010012239 Delusion Diseases 0.000 claims 4
- 231100000868 delusion Toxicity 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000004547 Hallucinations Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000006347 Intellectual Disability Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010021402 Illogical thinking Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 206010053632 Reactive psychosis Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008451 emotion Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516167.4A GB0516167D0 (en) | 2005-08-06 | 2005-08-06 | Pharmaceutical compounds |
| GB0516790A GB0516790D0 (en) | 2005-08-16 | 2005-08-16 | Pharmaceutical compounds |
| PCT/GB2006/002936 WO2007017654A1 (en) | 2005-08-06 | 2006-08-04 | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504622A JP2009504622A (ja) | 2009-02-05 |
| JP2009504622A5 true JP2009504622A5 (cg-RX-API-DMAC7.html) | 2009-09-24 |
Family
ID=37400949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525620A Ceased JP2009504622A (ja) | 2005-08-06 | 2006-08-04 | 医薬化合物 |
Country Status (20)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039627B2 (en) | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2463451A (en) * | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012135595A2 (en) | 2011-04-01 | 2012-10-04 | 3M Innovative Properties Company | Films including triazine-based ultraviolet absorbers |
| KR20160111999A (ko) | 2014-01-27 | 2016-09-27 | 오스펙스 파마슈티칼스, 인코포레이티드 | 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제 |
| CN113413385A (zh) * | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| HRP20240304T1 (hr) | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| EP4400171A3 (en) * | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US2843591A (en) | 1958-07-15 | Method for preparing same | ||
| CA2058640A1 (en) * | 1991-01-25 | 1992-07-26 | Richard R. Scherschlicht | Tricyclic pyridone derivative |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2770215B1 (fr) * | 1997-10-28 | 2000-01-14 | Pf Medicament | Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
-
2006
- 2006-08-04 EP EP06765238A patent/EP1855677B1/en active Active
- 2006-08-04 AT AT06765238T patent/ATE415968T1/de active
- 2006-08-04 WO PCT/GB2006/002936 patent/WO2007017654A1/en not_active Ceased
- 2006-08-04 PL PL06765238T patent/PL1855677T3/pl unknown
- 2006-08-04 PT PT06765238T patent/PT1855677E/pt unknown
- 2006-08-04 SI SI200630210T patent/SI1855677T1/sl unknown
- 2006-08-04 MX MX2008001549A patent/MX2008001549A/es active IP Right Grant
- 2006-08-04 DK DK06765238T patent/DK1855677T3/da active
- 2006-08-04 DE DE602006004009T patent/DE602006004009D1/de active Active
- 2006-08-04 RU RU2008108623/04A patent/RU2407743C2/ru not_active IP Right Cessation
- 2006-08-04 EP EP08170385A patent/EP2050451B1/en active Active
- 2006-08-04 RS RSP-2009/0055A patent/RS50807B/sr unknown
- 2006-08-04 AT AT08170385T patent/ATE534391T1/de active
- 2006-08-04 JP JP2008525620A patent/JP2009504622A/ja not_active Ceased
- 2006-08-04 HR HR20090074T patent/HRP20090074T3/xx unknown
- 2006-08-04 AU AU2006277753A patent/AU2006277753B2/en not_active Expired - Fee Related
- 2006-08-04 CA CA002620960A patent/CA2620960A1/en not_active Abandoned
- 2006-08-04 US US11/997,591 patent/US20110257220A1/en not_active Abandoned
- 2006-08-04 NZ NZ566011A patent/NZ566011A/en not_active IP Right Cessation
- 2006-08-04 KR KR1020087005308A patent/KR20080033500A/ko not_active Withdrawn
- 2006-08-04 ES ES06765238T patent/ES2318771T3/es active Active
-
2009
- 2009-02-26 CY CY20091100221T patent/CY1108843T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504622A5 (cg-RX-API-DMAC7.html) | ||
| JP2012520249A5 (cg-RX-API-DMAC7.html) | ||
| JP2009533356A5 (cg-RX-API-DMAC7.html) | ||
| PH12012501222A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| JP2005506370A5 (cg-RX-API-DMAC7.html) | ||
| BR112015008962A2 (pt) | silicato de zircônio microporoso para o tratamento de hipercalemia | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| RU2008108623A (ru) | Фармацевтические соединения | |
| WO2010080452A3 (en) | siRNA COMPOUNDS AND METHODS OF USE THEREOF | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| DE602005026007D1 (de) | Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd) | |
| JP2013507352A5 (cg-RX-API-DMAC7.html) | ||
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2012521966A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508758A5 (cg-RX-API-DMAC7.html) | ||
| JP2007516193A5 (cg-RX-API-DMAC7.html) | ||
| JP2017105861A5 (cg-RX-API-DMAC7.html) | ||
| ATE357453T1 (de) | Comt-inhibitoren | |
| JP2009501202A5 (cg-RX-API-DMAC7.html) | ||
| JP2007504168A5 (cg-RX-API-DMAC7.html) | ||
| JP2009500420A5 (cg-RX-API-DMAC7.html) | ||
| WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| PL1638559T3 (pl) | Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych |